| CLX |
Report |
Adjusted EPS |
BEAT |
pred ~$1.68 vs. cons $1.64 |
MEDIUM |
| CLX |
Report |
Net sales |
IN-LINE |
pred ~$1.90B vs. cons $1.91B |
MEDIUM |
| CLX |
Report |
Reported gross margin |
MISS |
pred ~41.2% vs. cons 41.8% |
MEDIUM |
| CLX |
Guide |
Adjusted EPS |
BETTER |
guide ~$6.20 vs. cons $6.03 (FY2027) |
MEDIUM |
| CLX |
Guide |
Net sales |
BETTER |
guide ~$7.55B vs. cons $7.52B (FY2027) |
LOW |
| CLX |
Guide |
Organic sales growth |
LOWER |
guide ~1.0% vs. cons 1.3% (FY2027) |
MEDIUM |
| CLX |
Guide |
Gross-margin change |
LOWER |
guide ~+70 bps vs. cons +110 bps (FY2027) |
MEDIUM |
| CLX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.5% |
— |
MEDIUM |
| CLX |
Return |
5-day cumulative residual |
+4.5% (FOLLOW-THROUGH) |
The modest EPS beat and FY2027 EPS framework of ~$6.20 versus ~$6.03 consensus should support upward out-period revisions, as the ~$0.90 ERP comparison reversal becomes visible in estimates. Follow-through is capped by weaker gross-margin guidance (~+70 bps versus +110 bps consensus) and only ~1.0% underlying organic growth. |
MEDIUM |